DOT drug testing changes effective January 1, 2018

The Department of Transportation (DOT) will now be consistent with other federal testing with expanded opiates added effective January 1, 2018. The DOT is amending its drug-testing program regulation to add hydrocodone, hydromorphone, oxymorphone, and oxycodone to its drug-testing panel; add methylenedioxyamphetamine as an initial test analyte, and remove methylenedioxyethylamphetamine as a confirmatory test analyte.

The revision of the drug-testing panel harmonizes DOT regulations with the revised HHS Mandatory Guidelines established by the U.S. Department of Health and Human Services for Federal drug-testing programs for urine testing. This final rule clarifies certain existing drug-testing program provisions and definitions, makes technical amendments and removes the requirement for employers and Consortium/Third Party Administrators to submit blind specimens.

See Federal Register at:  https://www.federalregister.gov/documents/2017/11/13/2017-24397/procedures-for-transportation-workplace-drug-and-alcohol-testing-programs-addition-of-certain

Recent Stories
AAOHN Foundation Announces 2018 Medique Research Grant

Official Journal of AAOHN Inducted Into Inaugural Nursing Journal Hall of Fame

AAOHN Member Barbara J. Burgel appointed to the California Occupational Health & Safety Standards Board